Abstract
The objectives of this phase I trial were to determine the maximally tolerated doses of the combination of epirubicin and paclitaxel with and without G-CSF (granulocyte colony stimulating factor) support and to investigate whether epirubicin pharmacokinetics are altered by paclitaxel. Patients with advanced cancer, performance status 0–2, and a normal left ventricular ejection fraction who had received up to 1 prior chemotherapy regimen were treated with epirubicin followed by a 3-hour infusion of paclitaxel repeated every 3 weeks. Dose levels studied were (paclitaxel/epirubicin) 155/75, 175/75, 175/90, 200/90 mg/m2 without G-CSF and 175/90 mg/m2 with G-CSF. Thirty-five patients were entered and all were assessable for toxicity. The dose-limiting dose level was 175 mg/m2 paclitaxel and 90 mg/m2 epirubicin with limiting toxicities of febrile neutropenia, diarrhea and esophagitis. The addition of G-CSF did not allow escalation of epirubicin. No significant cardiac toxicity was observed. Epirubicin pharmacokinetics were studied during the first 2 cycles in 6 patients, who were randomized to receive 1 cycle with no interval between the completion of the epirubicin and the commencement of the paclitaxel infusion and the other cycle with a 72-hour interval between the drugs. There was no substantial effect of paclitaxel on epirubicin or epirubicinol pharmacokinetics, although there was a marginal increase in glucoronidation. In conclusion, paclitaxel 175 mg/m2 and epirubicin 75 mg/m2 is recommended for phase II and III studies.
This is a preview of subscription content, access via your institution.
References
- 1.
Seidman AD, Reichman BS, Crown JPA et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13: 1152–1159, 1995
- 2.
Holmes FA, Madden T, Newman RA et al.: Sequencedependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713–2721, 1996
- 3.
Fisherman JS, Cowan KS, Noone K et al.: Phase I- II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-stimulating-factor in patients with metastatic breast cancer. J Clin Oncol 14: 774–782, 1996
- 4.
Sledge GW Jr, Robert M, Sparano JA et al.: Paclitaxel (taxol)-doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Sem Oncol 21 (Suppl 8): 15–18, 1994
- 5.
Gianni L, Munzone E, Capri G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995
- 6.
Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G et al.: Human pharmacokinetic characterisation and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15(5): 1906–1915, 1997
- 7.
Berg SL, Cowan KH, Bolis FM et al.: Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 62-hour infusion. J Natl Cancer Inst 86: 143–145, 1994
- 8.
Webster LK, Cosson EJ, Stokes KH, Millward MJ: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522-524, 1996
- 9.
Rischin D, Millward M, Webster L, Tinnelly K, Toner G, Bishop J et al.: Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs 5 (Suppl 1): 43–44, 1994
- 10.
Bonadonna G, Gianni L, Santoro A et al.: Drugs ten years later: Epirubicin. Ann Oncol 4: 359–369, 1993
- 11.
Zhang W, Zalcberg J, Cosolo W: Interaction of epirubicin with other cytotoxics and anti-emetic drugs. Anticancer Drugs 3: 593–597, 1992
- 12.
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15(7): 2510–2517, 1997
- 13.
Luck HJ, Thomssen C, du Bois A, Lisboa BW, Untch M, Kuhnle H, Janicke F, Meerpohl HG, Lindner C, Konecny G, Hecker D, Diegarten K: Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer. Sem Oncology 24(1) (Suppl 3): S3-13–S3-16, 1997
- 14.
Spielmann M, Catimel G, Bourgeois H, Pouillart P, Llombart-Cussac A, Rhor-Alvarado A, Le Grand A, Graffand N, Pellae-Cosset B: Taxol and farmorubicin in metastatic breast cancer: Preliminary results of phase I study. Ann Oncol 7 (Suppl 5), 1996
- 15.
Gehl J, Boesgard M, Paaske T et al.: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7: 687–693, 1996
- 16.
Gianni L, Dombernowsky P, Sledge G, Amadori M, Martin M, Baynes R, Arbuck S, Weil C, Tuck M, Messina M, Winograd B: Cardiac function following combination therapy with taxol and doxorubicin for advanced breast cancer. Proc ASCO 444, 1998
- 17.
Gianni L, Bigano L, Locatelli A, Giani A, Capri G, Bertuzzi A, Grasselli G, Tarenzi E, Bonadonna G: Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc ASCO 16, 1997
- 18.
Conte PF, Gennari A: Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol 8: 939–943, 1997
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Rischin, D., Webster, L.K., Millward, M.J. et al. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. Invest New Drugs 17, 73–80 (1999). https://doi.org/10.1023/A:1006219601797
Issue Date:
- taxanes
- anthracyclines
- pharmacology